- $19.79bn
- $20.19bn
- $982.02m
Guardant Health up as cancer detection test gets FDA's 'breakthrough' tag
Brief: Guardant Health Announced the results of the Serena-6 Phase III Trial
Brief: Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
U.S. RESEARCH ROUNDUP-American Tower, GoDaddy, Labcorp
U.S. RESEARCH ROUNDUP-Avepoint, Meta, United Therapeutics
Guardant Health Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Guardant Health Q1 Adjusted EPS USD -0.49 Vs. IBES Estimate USD -0.81
Brief: Guardant Health Announces Strategic Collaboration With Pfizer To Support Development And Commercialization Of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
Brief: Guardant Health And Bayshore Healthcare Partner To Expand Access To Advanced Precision Oncology Testing In Canada
Brief: Guardant Health Receives ADLT Status From CMS For Shield Blood Test
U.S. RESEARCH ROUNDUP-Intuit, Itron, Workday
Guardant Health sues rival Natera over cancer-testing trade secrets (updated)
Guardant Health sues Natera alleging trade secrets theft; shares of companies fall
Guardant Health sues rival Natera over cancer-testing trade secrets
U.S. RESEARCH ROUNDUP-Blue Owl Capital, Insulet, Unity Software
U.S. RESEARCH ROUNDUP-Blue Owl Capital, Insulet, Unity Software
Guardant Health Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Guardant Health Q4 Adjusted EPS USD -0.62 Vs. IBES Estimate USD -0.74
Brief: Guardant Health Announces Debt Exchange Transactions